IMNM | Immunome, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.41 - 6.85
52 Week Range	6.41 - 24.87
Beta	2.15
Implied Volatility	145.43%
IV Rank	53.77%
Day's Volume	6,213,472
Average Volume	977,886
Shares Outstanding	86,950,600
Market Cap	585,177,538
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-02

Valuation
Profitability
Growth
Health
P/E Ratio	-1.35
Forward P/E Ratio	N/A
EPS	-5.00
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	55
Country	USA
Website	IMNM

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

IMNM's peers: ANIX, ANVS, BHVN, CLNN, ANEB, ADAG, ACRV, ANAB, MLYS, MOLN, MNOV, CSBR, CYT, AVTE, RZLT, ANTX, GANX, TFFP, LIFE, INAB, LTRN, IKNA, CELC, TLSA

*Chart delayed

Analyzing fundamentals for IMNM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IMNM Fundamentals page.

Watching at IMNM technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMNM Technicals page.